Evidence map›Paper›PMID 32299911›Full record

ArticleThe Journal of biological chemistry2020

Antagonism between substitutions in β-lactamase explains a path not taken in the evolution of bacterial drug resistance.

Cameron A Brown, Liya Hu, Zhizeng Sun, Meha P Patel, Sukrit Singh, Justin R Porter, Banumathi Sankaran, B V Venkataram Prasad, Gregory R Bowman, Timothy Palzkill

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.0field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Cefdinir binding to a class A β-lactamase revealed by serial cryo-crystallography.Acta crystallographica. Section D, Structural biology · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Directed evolution of a beta-lactamase samples a wide variety of conformational states.Protein science : a publication of the Protein Society · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Cameron A BrownDepartment of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, Texas 77030.
Liya HuVerna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030.
Zhizeng SunDepartment of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, Texas 77030.
Meha P PatelDepartment of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, Texas 77030.
Sukrit SinghDepartment of Biochemistry & Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri 63110.
Justin R PorterDepartment of Biochemistry & Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri 63110.
Banumathi SankaranDepartment of Molecular Biophysics and Integrated Bioimaging, Berkeley Center for Structural Biology, Lawrence Berkeley National Laboratory, Berkeley, California 94720.
B V Venkataram PrasadVerna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030.
Gregory R BowmanDepartment of Biochemistry & Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri 63110.
Timothy PalzkillDepartment of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, Texas 77030; Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030. Electronic address: timothyp@bcm.edu.
Baylor College of Medicine · USWashington University in St. Louis · USLawrence Berkeley National Laboratory · US

Funding

User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI PAUL David ADAMS, Gregory L Hura · 2017 to 2026
$28.6M
BETA-LACTAMASE MUTATIONS IN ANTIBIOTIC RESISTANCER01AI032956 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI Timothy Palzkill · 1992 to 2026
$6.5M
MSMs, adaptive sampling, and data sharing on the cloudR01GM124007 · NIGMS · WASHINGTON UNIVERSITY · PI BOWMAN, GREGORY · 2017 to 2021
$2.0M
Training Interdisciplinary Pharmacology ScientistsT32GM120011 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI DESSAUER, CARMEN W. · 2016 to 2020
$1.0M
NIAID NIH HHS R01 AI032956NIGMS NIH HHS P30 GM124169NIGMS NIH HHS R01 GM124007NIGMS NIH HHS T32 GM120011
6 · The paper itself

Abstract

CTX-M β-lactamases are widespread in Gram-negative bacterial pathogens and provide resistance to the cephalosporin cefotaxime but not to the related antibiotic ceftazidime. Nevertheless, variants have emerged that confer resistance to ceftazidime. Two natural mutations, causing P167S and D240G substitutions in the CTX-M enzyme, result in 10-fold increased hydrolysis of ceftazidime. Although the combination of these mutations would be predicted to increase ceftazidime hydrolysis further, the P167S/D240G combination has not been observed in a naturally occurring CTX-M variant. Here, using recombinantly expressed enzymes, minimum inhibitory concentration measurements, steady-state enzyme kinetics, and X-ray crystallography, we show that the P167S/D240G double mutant enzyme exhibits decreased ceftazidime hydrolysis, lower thermostability, and decreased protein expression levels compared with each of the single mutants, indicating negative epistasis. X-ray structures of mutant enzymes with covalently trapped ceftazidime suggested that a change of an active-site Ω-loop to an open conformation accommodates ceftazidime leading to enhanced catalysis. 10-μs molecular dynamics simulations further correlated Ω-loop opening with catalytic activity. We observed that the WT and P167S/D240G variant with acylated ceftazidime both favor a closed conformation not conducive for catalysis. In contrast, the single substitutions dramatically increased the probability of open conformations. We conclude that the antagonism is due to restricting the conformation of the Ω-loop. These results reveal the importance of conformational heterogeneity of active-site loops in controlling catalytic activity and directing evolutionary trajectories.

Indexed as

beta-Lactam ResistanceEvolution, MolecularMutation, MissenseAmino Acid Substitutionbeta-LactamasesCatalysisCeftazidimeEscherichia coliEscherichia coli Proteinsbeta-lactamase CTX-M, E colibeta-LactamasesCeftazidimeEscherichia coli Proteinsantibiotic resistancebeta-lactam antibioticbeta-lactamasecephalosporinconformational changeenzyme kineticsenzyme mutationenzyme structureprotein conformationprotein crystallizationprotein drug interactionprotein stabilityprotein structure

Identifiers

PMID32299911
PMCPMC7247304
OpenAlexW3016316740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.